The colorectal adenoma-carcinoma sequence

British Journal of Surgery

Volumn 89, Issue 7, 2002, Pages 845-860

  Leslie, A ^a   Carey, F A ^a   Pratt, N R ^b   Steele, R J C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOMA; COLORECTAL CARCINOMA; COLORECTAL TUMOR; CYTOGENETICS; CYTOMETRY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HYPOTHESIS; MEDLINE; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW;

ADENOMA; ADENOMATOUS POLYPOSIS COLI PROTEIN; BASE PAIR MISMATCH; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA REPAIR; GENE DELETION; GENE EXPRESSION; GENES, P53; GENES, RAS; HUMANS; KARYOTYPING; MICROSATELLITE REPEATS; MUTATION;

EID: 0036063069     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2002.02120.x     Document Type: Review

References (206)

1. Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up
2. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps
3. Recurrence rates for colorectal polyps
4. Polyp guideline: Diagnosis, treatment, and surveillance for patients with colorectal polyps
5. Screening for colon malignancy with colonoscopy
6. Prevalence and malignant potential of colorectal polyps in asymptomatic, average-risk men
7. Screening colonoscopy in asymptomatic average-risk persons with negative fecal occult blood tests
8. The evolution of cancer of the colon and rectum
9. Prevalence of polyps in an autopsy series from areas with varying incidence of large-bowel cancer
10. Growth rate and malignant potential of colonic polyps: Early results
11. Natural history of untreated colonic polyps
12. Epidemiology of polyps in the rectum and colon. Recovery and evaluation of unresected polyps 2 years after detection
13. Lack of spontaneous regression of tubular adenomas in two years of follow-up
14. Endoscopic polypectomy: Inadequate treatment for invasive colorectal carcinoma
15. Morphology, anatomic distribution and cancer potential of colonic polyps
16. When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma?
17. Colonic adenomas - A colonoscopy survey
18. Remnants of adenomas in colorectal carcinomas
19. Factors influencing the prognosis of early cancer of the rectum
20. Incidence and therapeutic implications of synchronous colonic pathology in colorectal adenocarcinoma
21. The significance of synchronous carcinoma and polyps in the colon and rectum
22. The true incidence of synchronous cancer of the large bowel. A prospective study
23. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas
24. Prevention of colorectal cancer by colonoscopic polypectomy
25. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas
26. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer
27. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans
28. Polypectomy of adenomas in the prevention of colorectal cancer: 10 Years' follow-up of the Telemark Polyp Study I. A prospective, controlled population study
29. The effect of fecal occult-blood screening on the incidence of colorectal cancer
30. A minute chromosome in human chronic granulocytic leukaemia
31. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
32. Surfing the p53 network
33. Landscaping the cancer terrain
34. Allelic loss at SMAD4 in polyps from juvenile polyposis patients and use of fluorescence in situ hybridization to demonstrate clonal origin of the epithelium
35. Landscaper seeks remunerative position
36. A genetic model for colorectal tumorigenesis
37. Genetic alterations during colorectal-tumor development
38. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis
39. Localization of the gene for familial adenomatous polyposis on chromosome 5
40. Identification and characterization of the familial adenomatous polyposis coli gene
41. The somatic evolution of cancer. The Harveian Oration of 1996
42. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly
43. A role for the adenomatous polyposis coli protein in chromosomal segregation
44. APC binds to the novel protein EB1
45. Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein
46. Regulation of intracellular β-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein
47. β-Catenin is a target for the ubiquitin-proteasome pathway
48. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos
49. -/- colon carcinoma
50. Activation of β-catenin-Tcf signalling in colon cancer by mutations in β-catenin or APC
51. Transient excess of MYC activity can elicit genomic instability and tumorigenesis
52. C-myc overexpression and p53 loss cooperate to promote genomic instability
53. Identification of c-MYC as a target of the APC pathway
54. The APC gene product associates with microtubules in vivo and promotes their assembly in vitro
55. Wild-type but not mutant APC associates with the microtubule cytoskeleton
56. The adenomatous polyposis coli-binding protein EB1 is associated with cytoplasmic and spindle microtubules
57. Mutations in the APC tumour suppressor gene cause chromosomal instability
58. Mutations of mitotic checkpoint genes in human cancers
59. APC mutations occur early during colorectal tumorigenesis
60. Somatic mutations of the APC gene in colorectal tumors: Mutation cluster region in the APC gene
61. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors
62. Molecular determinants of dysplasia in colorectal lesions
63. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer
64. β-Catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas
65. ras oncogenes in human cancer: A review
66. The GTPase superfamily: A conserved switch for diverse cell functions
67. ras GTPase activating protein: Signal transmitter and signal terminator
68. Prevalence of ras gene mutations in human colorectal cancers
69. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis
70. Somatic mutations, acetylator status, and prognosis in colorectal cancer
71. Kirsten ras mutations in patients with colorectal cancer: The multicenter 'RASCAL' study
72. p53 expression and K-ras mutation in colorectal adenomas
73. Genetic epidemiology of mutated K-ras proto-oncogene, altered suppressor genes, and microsatellite instability in colorectal adenomas
74. K-RAS-2 gene mutations as predictors of metachronous colorectal adenomas
75. Ki-ras mutations in adenomas: A characteristic of cancer-bearing colorectal mucosa
76. K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients
77. Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Its potential as a biomarker of colorectal tumorigenesis
78. TP53 tumour suppressor gene: A model for investigating human mutagenesis
79. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
80. Clonal analysis of human colorectal tumors
81. The TP53 tumour suppressor gene in colorectal carcinomas. I. Genetic alterations on chromosome 17
82. Consistent deficiencies of chromosome 18 and of the short arm of chromosome 17 in eleven cases of human large bowel cancer: A possible recessive determinism
83. Introduction: p53 - The first twenty years
84. Twenty years of p53 research: Structural and functional aspects of the p53 protein
85. p53, guardian of the genome
86. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma
87. Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors
88. Chromosomal gains and losses in primary colorectal carcinomas detected by CGH and their associations with tumour DNA ploidy, genotypes and phenotypes
89. Specific patterns of chromosomal abnormalities are associated with RER status in sporadic colorectal cancer
90. Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53
91. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
92. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein
93. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding
94. p53 mutations in colorectal cancer
95. Genetic events in sporadic colorectal adenomas: K-ras and p53 heterozygous mutations are not sufficient for malignant progression
96. Immunohistochemical analysis of p53 overexpression in human colonic tumors
97. A frequent alteration of p53 gene in carcinoma in adenoma of colon
98. Overexpression of p53 protein and proliferative activity in colorectal adenoma
99. p53 expression in colorectal adenomas
100. Staining patterns of p53 immunohistochemistry and their biological significance in colorectal cancer
101. Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression
102. Identification of a chromosome 18q gene that is altered in colorectal cancers
103. Deleted in colorectal cancer (DCC) encodes a netrin receptor
104. Phenotype of mice lacking functional deleted in colorectal cancer (Dcc) gene
105. The DCC gene: Structural analysis and mutations in colorectal carcinomas
106. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
107. TGF-β signalling from cell membrane to nucleus through SMAD proteins
108. Smad4 (DPC4) - A potent tumour suppressor?
109. Targeted deletion of Smad4 shows it is required for transforming growth factor β and activin signaling in colorectal cancer cells
110. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor β signaling by targeting Smads to the ubiquitin-proteasome pathway
111. Frequency of Smad gene mutations in human cancers
112. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers
113. Mad-related genes in the human
114. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma
115. Mutations in the SMAD4/DPC4 gene in juvenile polyposis
116. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer
117. DNA methylation and genomic imprinting
118. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality
119. CpG-rich islands and the function of DNA methylation
120. Alterations in DNA methylation may play a variety of roles in carcinogenesis
121. DNA methylation errors and cancer
122. Hypomethylation of DNA from benign and malignant human colon neoplasms
123. Reduced genomic 5-methylcytosine content in human colonic neoplasia
124. Mutagenicity of 5-azacytidine and related nucleosides in C3H/10T1/2 clone 8 and V79 cells
125. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells
126. Suppression of intestinal neoplasia by DNA hypomethylation
127. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer
128. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
129. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
130. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers
131. Mechanisms of inactivation of mismatch repair genes in human colorectal cancer cell lines: The predominant role of hMLH1
132. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
133. Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer
134. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer
135. Association between CpG island methylation and microsatellite instability in colorectal cancer
136. DNA mismatch repair genes and colorectal cancer
137. Diagnostic microsatellite instability: Definition and correlation with mismatch repair protein expression
138. + tumor cells
139. Mutator phenotype may be required for multistage carcinogenesis
140. Clues to the pathogenesis of familial colorectal cancer
141. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients
142. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer
143. Microsatellite instability in cancer of the proximal colon
144. Morphology of sporadic colorectal cancer with DNA replication errors
145. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
146. Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history
147. Management of colorectal polyps
148. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome
149. Genomic instability in neoplasia
150. Microsatellite instability in colorectal cancer: Different mutator phenotypes and the principle involvement of hMLH1
151. BAT-26 and BAT-40 instability in colorectal adenomas and carcinomas and germline polymorphisms
152. Clinical implications of microsatellite instability in colorectal cancers
153. Genomic instability in colorectal carcinomas. Comparison of different evaluation methods and their biological significance
154. Alternative genetic pathways in colorectal carcinogenesis
155. Microsatellite instability is associated with the histological features of the tumor in nonfamilial colorectal cancer
156. Microsatellite instability in colorectal adenomas
157. Genomic instability occurs in colorectal carcinomas but not in adenomas
158. Deletion of 1p loci and microsatellite instability in colorectal polyps
159. Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas
160. DNA microsatellite instability and mismatch repair protein loss in adenomas presenting in hereditary non-polyposis colorectal cancer
161. Lessons from hereditary colorectal cancer
162. Mutation of a mutL homolog in hereditary colon cancer
163. Mutation of a mutS homolog in hereditary nonpolyposis colorectal cancer
164. Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas
165. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability
166. Update of genetics in colorectal carcinomas: Genomic instability and somatic evolution
167. Genetic instabilities in human cancers
168. Genetic instability in colorectal cancers
169. Cytogenetics of colorectal adenocarcinomas
170. Karyotypic characterization of colorectal adenocarcinomas
171. Karyotypic characteristics of colorectal tumors
172. Clonal karyotypic abnormalities in colorectal adenomas: Clues to the early genetic events in the adenoma-carcinoma sequence
173. Cytogenetic analysis of intestinal polyps in polyposis syndromes: Comparison with sporadic colorectal adenomas
174. Chromosome analysis of adenomatous polyps of the colon: Possible existence of two differently evolving cytogenetic groups
175. Trisomy 7 in nonneoplastic cells
176. Localization of a candidate colon tumour-suppressor gene (DRA) to 7q22-q31.1 by fluorescence in situ hybridization
177. Identification of a colon mucosa gene that is down-regulated in colon adenomas and adenocarcinomas
178. Down-regulation of the down-regulated in adenoma (DRA) gene correlates with colon tumor progression
179. Deletion of 1p36 as a primary chromosomal aberration in intestinal tumorigenesis
180. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors
181. Comparative genomic hybridization and chromosomal instability in solid tumours
182. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation
183. Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization
184. Comparative genomic hybridization analysis of primary colorectal carcinomas and their synchronous metastases
185. Analysis of colorectal cancer by comparative genomic hybridization: Evidence for induction of the metastatic phenotype by loss of tumor suppressor genes
186. Comparative genomic in situ hybridization of colon carcinomas with replication error
187. DNA ploidy and cell-cycle analysis: Tools for assessment of cancer prognosis
188. Tumor DNA content in resectable, primary colorectal carcinoma
189. Prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas
190. The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study
191. The relationship of DNA aneuploidy to molecular genetic alterations in colorectal carcinoma
192. Multiparameter flow cytometric analysis of colon polyps
193. DNA aneuploidy in colorectal adenomas
194. DNA microarrays in medical practice
195. Genome-wide screening of genes showing altered expression in liver metastases of human colorectal cancers by cDNA microarray
196. Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia
197. Construction of preferential cDNA microarray specialized for human colorectal carcinoma: Molecular sketch of colorectal cancer
198. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays
199. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array
200. Assessment of differential gene expression patterns in human colon cancers
201. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis
202. Identification of tumor markers in models of human colorectal cancer using a 19 200-element complementary DNA microarray
203. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring